RIST Improves PFS in Relapsed/Refractory Neuroblastoma
Rapamycin, dasatinib, irinotecan, and temozolomide (RIST) improves progression-free survival vs irinotecan and temozolomide in relapsed/refractory neuroblastoma, a phase 2 trial suggests.
American Society of Clinical Oncology (ASCO)
Cancer Vaccine mRNA-4157 Improves RFS, DMFS in High-Risk Melanoma
Adding the mRNA-4157 vaccine to pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk, resected melanoma in a phase 2 trial.
Sacituzumab Govitecan Improves OS and PFS in HR+, HER2- Metastatic Breast Cancer
Sacituzumab govitecan improves outcomes vs physician’s choice of treatment in patients with endocrine-resistant, HR+, HER2- metastatic breast cancer, results from the phase 3 TROPiCS-02 study suggest.
Nivolumab Plus AVD Could Be New Standard Care in Classic Hodgkin Lymphoma
Nivolumab plus chemotherapy appears more effective than brentuximab vedotin plus chemotherapy in patients with advanced stage classic Hodgkin lymphoma.
Immune Checkpoint Inhibitor Rechallenge of No Benefit in Advanced RCC
Immune checkpoint inhibitor rechallenge did not improve outcomes in patients with advanced renal cell carcinoma in the phase 3 CONTACT-03 trial.
Trastuzumab Deruxtecan Shows Activity in HER2+ Metastatic Colorectal Cancer
Trastuzumab deruxtecan elicits responses in patients with HER2-positive metastatic colorectal cancer, a phase 2 study suggests.
Erdafitinib Bests Chemotherapy in FGFR-Altered Metastatic Urothelial Carcinoma
Erdafitinib improves survival vs chemotherapy in patients with metastatic urothelial carcinoma and select FGFR alterations who were previously treated with immune checkpoint inhibitors, a phase 3 trial suggests.
Neoadjuvant Chemo Appears No Better Than Upfront Surgery for Colon Cancer
Neoadjuvant chemotherapy does not improve survival outcomes vs upfront surgery in patients with locally advanced colon cancer, a phase 3 trial suggests.
Perioperative Toripalimab and Chemo Deemed Potential Standard Care in Stage III NSCLC
Perioperative toripalimab plus chemotherapy improves event-free survival over chemotherapy alone in stage III non-small cell lung cancer, a phase 3 study suggests.
First-Line Pembrolizumab Improves Survival in Metastatic Cervical Cancer
Updated data support the use of pembrolizumab in combination with chemotherapy as first-line standard care for patients with persistent, recurrent, or metastatic cervical cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2023 Gastrointestinal Cancer In-Depth
Loading... 
Loading...